Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies

• Published in: Journal of the Anus, Rectum and Colon Vol. 8; no. 2; pp. 132 - 136
• Main Authors: Kataoka, Kozo, Yamada, Takeshi, Shiozawa, Manabu, Takase, Naoto, Ito, Kazuma, Yamazaki, Kentaro, Watanabe, Jun, Kudo, Toshihiro, Suto, Takeshi, Matsumoto, Toshihiko, Murata, Kohei, Suwa, Yusuke, Boku, Shogen, Yasui, Hisateru, Matsuhashi, Nobuhisa, Maeda, Atsuyuki, Sugimoto, Kiichi, Matsumoto, Yusuke, Yokota, Mitsuru, Fredebohm, Johannes, Mori, Keita, Ikeda, Masataka
• Format: Journal Article
• Language: English
• Published: Japan The Japan Society of Coloproctology 25.04.2024
• Subjects: anti-EGFR monoclonal antibody; colorectal cancer; ctDNA; RAS-trace; RAS-trace-2; Trial Protocol; RAS-trace; colorectal cancer; anti-EGFR monoclonal antibody; RAS-trace-2; ctDNA
• ISSN: 2432-3853; 2432-3853
• DOI: 10.23922/jarc.2023-051

Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acquired RAS mutation is sometimes observed at disease progression of treatment with the anti-EGFR mAb. At the same time, discrepancy of RAS status from tissues and circulating tumor DNA (ctDNA) in the same patient is sometimes observed. Based on this, we commenced two observational studies to clarify these heterogeneities of RAS and BRAF in mCRC, using next generation sequencing from liquid biopsy.Methods/Design: RAS-trace study is an observational study to monitor ctDNA RAS/BRAF/PIK3CA status every 4-12 weeks using the Plasma-SeqSensei™ CRC RUO Kit (Sysmex Inostics GmbH) in mCRC with RAS/BRAF wild-type (wt) on tumor tissue. The primary endpoint was the time to the acquired RAS mutations. A total of 42 patients has been accrued. RAS-trace-2 study is also an observational study aimed at comparing the efficacy of the anti-EGFR mAb in ctDNA RAS/BRAF wt with ctDNA RAS or BRAF mutant mCRC patients, whose RAS/BRAF are wt in tumor tissue. The primary endpoint was progression-free survival in patients with ctDNA RAS/BRAF wt and RAS or BRAF mutant. A total of 240 patients will be accrued over 2 years.Discussion: These trials will help us understanding the clinical significance of spatial and temporal heterogeneities of RAS, BRAF and other genes, while optimizing the anti-EGFR mAb treatment strategies in mCRC.